In persons at intermediate risk for CVD, polypills reduce a composite of CV events at 5 y

Krysta Brown; Anthony A Donato

doi:10.7326/J21-0004

In persons at intermediate risk for CVD, polypills reduce a composite of CV events at 5 y

Ann Intern Med. 2022 Jan;175(1):JC2. doi: 10.7326/J21-0004. Epub 2022 Jan 4.

Authors

Krysta Brown¹, Anthony A Donato¹

Affiliation

¹ Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).

PMID: 34978850
DOI: 10.7326/J21-0004

Abstract

Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398:1133-46. 34469765.

Publication types

Comment

MeSH terms

Aspirin / therapeutic use
Cardiovascular Diseases* / prevention & control
Drug Combinations
Humans
Primary Prevention

Substances

Drug Combinations
Aspirin